VANDA PHARMACEUTICALS INC. Deferred Tax Assets, Deferred Income
VANDA PHARMACEUTICALS INC. (VNDA) had Deferred Tax Assets, Deferred Income of $36.67 million as of 2013-12-31, per its 10-K filed 2015-03-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2015-03-13
- 2013-12-31: Deferred Tax Assets, Deferred Income $36.67M.
- 2012-12-31: Deferred Tax Assets, Deferred Income $47.51M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2013-12-31 | $36.67M 10-K · filed 2015-03-13 |
| 2012-12-31 | $47.51M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |